Publications
P300
RSC Med. Chem. 2025, 16, 3746–3763.
Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy
https://doi.org/10.1039/D5MD00257E
P290
ChemMedChem. 2025, 20, e202400862.
Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.
https://doi.org/10.1002/cmdc.202400862
P250
Phytochem. Lett. 2022, 50, 57-60.
Amino ether analogues of 4,4′-dihydroxy-3-methoxy-6,7′-cyclolignan and their activity against drug-resistant bacteria.
https://doi.org/10.1016/j.phytol.2022.05.004
P240
Molecules 2021, 26, 6572.
Dibenzofuran derivatives inspired from cercosporamide as dual inhibitors of Pim and CLK1 kinases.
doi: 10.3390/molecules26216572
P234
Med. Chem. Res. 2021, 30, 152-162.
Antimicrobial and anti-leishmanial activities of extracts and some constituents from the leaves of Solanum chrysotrichum Schldl.
doi: 10.1007/s00044-020-02648-8
P231
Eur. J. Med. Chem. 2021, 210, 112956.
In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.
doi: 10.1016/j.ejmech.2020.112956
P202
Pharmaceuticals 2019, 12, 169.
Biological evaluation of arylsemicarbazone derivatives as potential anticancer agents.
doi:10.3390/ph12040169
P199
Curr. Top. Med. Chem. 2019, 19, 1075-1091.
5-Nitro-thiophene-thiosemicarbazone derivatives present antitumor activity mediated by apoptosis and DNA intercalation.
doi: 10.2174/1568026619666190621120304
P182
Tetrahedron Lett. 2018, 59, 3519-3523.
Novel approach towards 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones exploiting cross-coupling and SNAr reactions of a dihalogenated compound.
doi: 10.1016/j.tetlet.2018.08.013
P181
J. Heterocycl. Chem. 2018, 55, 1101-1111.
Design and synthesis of imidazo[1,2-a]pyridines with carboxamide group substitution and in silico evaluation of their interaction with a LuxR-type quorum sensing receptor.
doi: 10.1002/jhet.3140
P173
Bioorg. Med. Chem. Lett. 2018, 28, 2250-2255.
Benzofuro[3,2-d]pyrimidines inspired from cercosporamide CaPkc1 inhibitor: synthesis and evaluation of fluconazole susceptibility restoration.
doi: 10.1016/j.bmcl.2018.05.044
P168
X-Ray Struct. Anal. Online 2017, 33, 41-43.
Crystal structure of N-(7-{[2-(dimethylamino)ethyl]amino}-1-methyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-3,4,5-trimethoxybenzamide.
doi: 10.2116/xraystruct.33.41
P156
Eur. J. Med. Chem. 2016, 119, 17-33.
Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.
doi: 10.1016/j.ejmech.2016.04.050
P155
Anticancer Res. 2016, 36, 1621-1630.
Discovery of (imidazo[1,2-a]pyrazin-6-yl)ureas as antiproliferative agents targeting P53 in non-small cell lung cancer cell lines.
P141
Tetrahedron 2015, 71, 3303-3313.
Efficient one-pot synthesis of 3,7-disubstituted 1,6-naphthyridin-2(1H)-ones through regioselective palladium-catalyzed cross-coupling and SNAr reactions.
doi: 10.1016/j.tet.2015.03.110
P136
Eur. J. Med. Chem. 2015, 103, 381-395.
Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.
doi: 10.1016/j.ejmech.2015.09.002
P125
Eur. J. Org. Chem. 2014, 7, 1487-1495.
Differential functionalization of 1,6-naphthyridin-2(1H)-ones through sequential one-pot Suzuki-Miyaura cross-couplings.
P121
Eur. J. Med. Chem., 2013, 69, 823-832.
Synthesis and antiproliferative activity of benzofuran-based analogs of cercosporamide against non-small cell lung cancer cell lines.
P117
Tetrahedron Lett., 2013, 54, 5378-5382.
Exploration of versatile reactions on 2-chloro-3-nitroimidazo[1,2-a]pyridine: expanding structural diversity of C2- and C3-functionalized imidazo[1,2-a]pyridines.
P108
Eur. J. Med. Chem., 2012, 58, 543-556.
Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.
Autres publications scientifiques
Brevets
Thèse